HeyJaredJason Laday
- Indexed articles, last 90 days
- 4
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Healio
- Top 500K sites
- Earliest in this view
- Jul 21, 2026
Latest articles
FDA to remove references to animal testing in drug safety regulations (opens the original)
Read excerpt
The FDA has issued a final rule that would remove references to animal studies in its drug safety regulations, as part of a larger effort across HHS to reduce what it calls “unnecessary animal testing” in biomedical research. In addition to the new FDA rule, which would take effect Feb. 4, 2027, the NIH simultaneously announced a series of new initiatives intended to develop and promote alternatives to animal testing, including more than $88 million in funding for biomedical infrastructure proje
Speaker: CAR T-cell trial deaths add âsobrietyâ to discussions with autoimmune patients (opens the original)
Read excerpt
HUNTINGTON BEACH, Calif. — The deaths of three participants in trials of Novartis’ chimeric antigen receptor T-cell therapy for autoimmune disease will “add some sobriety” to discussions with patients, according to a speaker. “We’re in the very early days of learning about this,” Philip J. Mease, MD, MACR, FRCP, director of the rheumatology clinical research division at Swedish Medical Center/Providence St. Joseph Health, in Seattle, told Healio in an interview. “But it will have an impact on th
Amgen rejects FDA claims of avacopan study manipulation, submits new data (opens the original)
Read excerpt
Amgen has submitted new re-adjudication data alongside real-world, post-marketing and meta-analysis studies in support of avacopan, arguing the drug maintains a positive risk-benefit ratio and should remain on the market. In a 104-page document submitted to the FDA and provided to Healio, representatives from Amgen also rejected allegations levied by the FDA that employees of avacopan’s (Tavneos, Amgen) original manufacturer, ChemoCentryx, “manipulated” data in the ADVOCATE trial, the sole study
CMS announces 2027 Medicare pay cut as ACR decries âbreaking pointâ for physicians (opens the original)
Read excerpt
The newly proposed Medicare fee schedule for 2027 would cut physician pay by 1.68%, or 1.19% for those participating in qualifying alternative payment models, according to a fact sheet released by CMS. The projected Medicare Physician Fee Schedule (PFS) for 2027, which CMS unveiled July 14, includes a conversion factor of $33.17 for physicians who participate in qualifying alternative payment models (APM), representing a decrease of $0.40 (–1.19%) from the current conversion factor of $33.57. Me
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 500K sites
For Healio, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.